• Ligand agreed to buy XOMA Royalty for USD 39 per share in cash, valuing the equity at about USD 739 million.
• XOMA Royalty holders will also receive one non-transferable CVR per share tied to 75% of net proceeds from pending TREMFYA litigation.
• Ligand expects to fund the deal with cash on hand, borrowing under its existing credit facility.
• Closing is targeted for Q3 2026, subject to XOMA Royalty shareholder vote and regulatory clearances.
• Ligand raised 2026 adjusted EPS guidance to USD 8.5-9.5, expecting immediate accretion and a USD 1.5 boost in 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. XOMA Royalty Corporation published the original content used to generate this news brief on June 12, 2026, and is solely responsible for the information contained therein.